MET/HGF mutations and overexpression are present in a high percentage of GBM tumors and previous studies have demonstrated that inhibition of MET in tumor cells leads to growth inhibition, tumor regression and decreased metastatic potential. This evidence concerns the gene HGF and neoplasm.